The latest news from ItaCRIN and its partners

News

The 7th issue of COVID-19 Clinical Trial Report is now online!

Thursday, November 26, 2020,

The COVID-19 Clinical Trial report series is going on to update you with current data and insights on clinical trials authorized throughout the COVID-19 pandemic.

In this issue, the COVID-19 Clinical Trial team of the National Institute of Health (ISS) dedicated a section to the Italian studies with convalescent plasma and a special focus on the TSUNAMI Study, whose sponsors are ISS and the Italian Competent Authority, AIFA.
Click here to view the report 👉https://www.epicentro.iss.it/coronavirus/sars-cov-2-analisi-studi-interventistici 

PRE-ANNOUNCEMENT JTC 2021

Friday, October 23, 2020,

ERA PerMed is an ERA-Net Cofund, supported by 32 partners of 23 countries and co-funded by the European Commission. To align national research strategies, promote excellence, reinforce the competitiveness of European players in Personalised Medicine (PM), and enhance the European collaboration with non-EU countries, 28 funding organisations have agreed to launch the fourth Joint Transnational Call for collaborative innovative research projects in PM.

The funding organisations participating in this call particularly wish to promote innovative interdisciplinary collaboration and to encourage translational research proposals.

The call is planned to be launched on December 14th 2020 with a submission deadline for pre-proposals on March 4th 2021. It is expected that consortia invited for the full-proposal stage, will need to submit their proposal on June 16th, 2021.

Download the full text of the ERA PerMed JTC2021 pre-announcement here (updated 16 Oct 2020) 👉 PRELIMINARY ANNOUNCEMENT JTC 2021

ECRIN signed the Manifesto for EU COVID-19 Research

Friday, October 16, 2020,

The Commission has launched a manifesto to maximise the accessibility of research results in the fight against COVID-19.

The Manifesto provides guiding principles for beneficiaries of EU research grants for coronavirus prevention, testing, treatment and vaccination to ensure that their research results will be accessible for all and guarantee a return on public investment.

To read and/or endorse the Manifesto, please visit the website. 

Don't miss the 6th issue of COVID-19 Clinical Trial Report!

Thursday, October 15, 2020,

On 12th October, the COVID-19 Clinical Trial team of the National Institute of Health (ISS) released the 6th report showing the status quo of the interventional studies conducted in Italy (45 authorized by AIFA) and worldwide. Up to date the total number of clinical studies registered on ClinicalTrials.gov are 1972. 42 are the COVID-19 candidate vaccines under clinical evaluation and the related currently running studies are 75.
Read more here

The 5th issue of COVID-19 Clinical Trial Report is now available!

Thursday, September 17, 2020,

After summer break, the 5th issue on Covid-19 clinical trial studies has been published by the Clinical Trial
working group of ISS. 
This week a dedicated section of the Italian vaccine GRAd-COV2 will be available.

Read more about here

Announcing EOSC-Life's Digital Life Sciences Open Call

Tuesday, September 15, 2020,

EOSC-Life has launched its first Digital Life Sciences Open Call: A European Open Science Cloud (EOSC-Life) call for projects sharing data, tools and workflows in the cloud.

This call offers financial support for projects enabling life science researchers to connect their research to the cloud, alongside with training, advice and assistance from data experts, tool developers and cloud specialists.

Deadline for proposal submission is 22 December 2020.

Find out more about eligibility, application and review processes and budgeting by visiting www.eosc-life.eu/opencall.

 

ECRIN Annual Report 2019 is now available!

Friday, August 7, 2020,

We are excited to announce that the ECRIN Annual Report 2019 is now available on ECRIN website.

See the report on how we support multinational Clinical Trials and Infrastructure development projects to enhance medical practice and to improve public health to this link: https://ecrin.org/sites/default/files/annual%20reports/Annual-Report-A4-ECRIN-2019.pdf.

 

A Swedish SMO interested in conducting a multinational clinical trial to test a medical device for depression is seeking collaboration with ECRIN!

Wednesday, August 5, 2020,

Located in Sweden, Flow Neuroscience provides a CE-certified complete at-home depression treatment combining a transcranial direct current stimulation (tDCS) headset with a behavioural therapy application.

Flow is currently seeking research partners in the EU to conduct a multinational clinical trial program on the efficacy of our product in the treatment of anxiety. Flow, together with the research partners, will apply for the Horizon2020 European Commission grant (EIC Accelerator Pilot - up to €2.5M funding) that is dedicated to fund early-stage innovations. To orchestrate the multinational clinical trial program, we are also seeking collaboration with ECRIN.
In the partnership, Flow will be solely responsible for the preparation of the grant application. Clinical studies under the partnership will be fully funded by the grant (expected launch: Q3/Q4 2021).

If interested in discussing this potential research collaboration, please contact us!
📬 elena.toschi@iss.it; maria.buoncervello@iss.it

July 2020 ECRIN newsletter is now online!

Monday, August 3, 2020,

Don't forget the ECRIN's July 2020 edition of its newsletter. This issue includes updates on infrastructure development projects, National partners, COVID-19 Taskforce, and more.

👉 July 2020 issue

Don’t miss the 4th issue of COVID-19 Clinical Trial Report!

Thursday, July 30, 2020,

In the new issue, the Clinical Trial working group of ISS is keeping a close eye on evolving Covid-19 vaccines.

Read more about the 4th issue here

See you with the next report after summer break!

The 3rd issue of COVID-19 Clinical Trial Report is now online!

Thursday, July 9, 2020,

We continue the COVID-19 Clinical Trial Report series – bringing you current data on clinical studies approved in Italy and around the world.


Click to view the new report, past reports and methodological note.

Join the 2nd issue of COVID-19 Clinical Trial Report!

Friday, June 19, 2020,

Don't miss out on the 2nd Edition of issue of COVID-19 Clinical Trial Report.

To view and read the report, please visit the link https://www.epicentro.iss.it/coronavirus/sars-cov-2-analisi-studi-interventistici 

COVID-19 Clinical Trial Report

Friday, June 12, 2020,

It is our pleasure to announce that the COVID-19 Clinical Trial team of the National Institute of Health (ISS) has launched a Clinical Trial Report related to Coronavirus emergency. In the report are mapped and monitored the interventional pharmacological clinical studies and vaccines for the treatment and prevention of SARS-CoV-2 infection. Furthermore, the related data are analyzed (i.e. study design, enrollment, phases, status, ... ). In addition, a special focus on the Italian landscape is described.
The COVID-19 Clinical Trial report is bi-weekly updated through the collection and elaboration of data from the most important sources of information worldwide.
To view and read the report, please visit the link https://www.epicentro.iss.it/coronavirus/sars-cov-2-analisi-studi-interventistici (or contact Lucia Palmisano via mail at lucia.palmisano@iss.it)

Five practical steps to accelerate COVID-19 research

Monday, June 8, 2020,

ECRIN, together with EATRIS and BBMRI, published top 5 recommendations to accelerate COVID19 research.

Read the paper on EURACTIV.

Research Data Alliance COVID-19 recommendations and guidelines

Wednesday, June 3, 2020,

The Research Data Alliance recently published the pre-final version of their guidelines and recommendations on data sharing in the context of COVID-19. An open consultation period has begun which will close on 8 June.
Please see attached a cover statement providing some context and the links to both the guidelines and the website through which to provide feedback.

They encourage to share this cover statement widely among communities to ensure that as many stakeholders as possible have the opportunity to shape this very useful resource.

Feedback can be provided by following this link: https://www.rd-alliance.org/group/rda-covid19-rda-covid19-omics-rda-covid19-epidemiology-rda-covid19-clinical-rda-covid19-0

Clinical Research Metadata Repository launched

Thursday, May 7, 2020,

It is our pleasure to announce that ECRIN has launched a Clinical Research Metadata Repository, including COVID-19 data, allowing the discovery of clinical studies and related data objects (i.e. protocol, information sheet and consent form, data management plan, statistical analysis plan, case report form, results, publications, etc.).
The COVID-19 Clinical Research Metadata Repository is updated regularly through collection of data from the most important sources of information worldwide.
For any further information on the ECRIN COVID-19 Taskforce or the Clinical Research Metadata Repository, please contact ECRIN’s Head of Clinical Operations Unit, Sabine Kläger via mail at sabine.klager@ecrin.org.

International Clinical Trials Day 2020 cancelled

Monday, May 4, 2020,

Due to the current COVID-19 pandemic, the International Clinical Trials Day 2020 in Berlin has been cancelled. The next International Clinical Trials Day will be held on May 27th 2021 in Berlin. The topic of ICTD 2021 will be (patient-)recruitment in clinical trials.
Please, reschedule your agenda to:
Date: 27 May 2021

Location: Berlin, Germany

A new CTU joined ItaCRIN Network!

Wednesday, April 22, 2020,

It is a great pleasure to announce that the Clinical trial Unit of University of Milan-Bicocca
(BICRO) is now part of the ItaCRIN Network.
Welcome BICRO!

COVID-19 Data Portal

Tuesday, April 21, 2020,

The COVID-19 Data Portal was launched yesterday to bring together relevant datasets for sharing and analysis to accelerate coronavirus research. It enables researchers to upload, access and analyse COVID-19 related data and specialist datasets as part of the wider European COVID-19 Data Platform.
For more detailed information, please visit https://www.covid19dataportal.org/

BBMRI, ECRIN AND EATRIS against COVID-19 pandemic

Friday, April 10, 2020,

The three Research Infrastructures are working together under the umbrella of the Alliance of Medical Research Infrastructures (AMRI).

The full catalogue of AMRI resources is available to the COVID-19 research community.

For more information please follow the guidance provided here or contact EATRIS Business Development Manager directly: christieken@eatris.eu; +31(0) 6155 66487 on how to access to the services.

TRANSVAC2 offers a support to the development of vaccines against COVID19

Wednesday, April 8, 2020,

TRANSVAC supports innovation for both prophylactic and therapeutic vaccine development. High quality technical services across four different service platforms are offered: Technology (for process development and GMP production), Immunocorrelates & Systems Biology, Animal models, and support for Clinical Trials. Academic and non-academic research groups, including SMEs, can apply to benefit from the expertise, reagents, and facilities offered by TRANSVAC2 to accelerate the development of their vaccines.​

TRANSVAC2 extended the deadline for submission of applications for the M13 and M14 training module on Systems Biology of Vaccinology and Regulatory aspects of vaccine development
For more information, please visit: https://www.transvac.org/

ECRIN contribution to COVID-19 research

Wednesday, April 1, 2020,

In the COVID-19 emergency, ECRIN has established, with its national partners, a COVID-19 taskforce with its national partners, working on a fast-track procedure for access to, and provision of services:

  1. Review and digest the scientific literature on COVID clinical trials
  2. Develop a metadata repository for COVID trials making all the non-sensitive COVID-19 trial data accessible
  3. Develop a database on the regulatory, ethical and data protection fast track approvals across all European countries
  4. Ensure preparedness of its national clinical trial unit (CTU) partners for COVID trials
  5. Combine and coordinate national initiatives to promote multinational rather than national trials, including through connection with national funders, sponsors investigators and CTUs
  6. Develop partnership with national and pan-European investigation networks on infectious diseases and intensive care
  7. Outreach to investigators, sponsors, patients, policymakers, funders, and citizens
  8. International cooperation and outreach, including with WHO and through CRIGH and other initiatives.

For any further information please contact ECRIN’s Head of Clinical Operations Unit, Sabine Kläger via mail at sabine.klager@ecrin.org

#StopTheSpread

Monday, March 30, 2020,

Consistent with Covid-19 outbreak and subsequent measures adopted by the Italian Council of Ministers in conjunction with the Ministry of Health, no-profit Sponsors, CTUs/CROs and many pharmaceutical companies have applied or extended smart-working in order to continue their activities related to clinical trials and to assure at the same time the highest possible protection of the personnel involved. To this regard, please see the AIFA announcement.

A new CTU joined ItaCRIN Network!

Friday, February 21, 2020,

It is our great pleasure to announce that CD PHARMA became part of ItaCRIN.
Our Network is growing fast,

Welcome CD PHARMA!

www.cdpharma.it

EJP RD – RDR Challenges NETWORKING EVENT ANNOUNCEMENT

Friday, January 10, 2020,

Summary information on the RDR Challenges Call

The RDR Challenges call will be launched in March 2020.

It foresees selection, evaluation and funding of projects in a 2-stage process. Challenges must be solvable in a short time period of 30 months with first milestones/deliverables at M18. A first Scientific Evaluation Committee (SEC) meeting will evaluate applications responding to the proposed challenges for the first 18-month phase grant. The aim of this selection process is to fund one project for each proposed challenge. Following the completion of the first phase (after 18 months), the applicants submit a report demonstrating the work undertaken during the study and, if appropriate, an application for phase 2 funding. The SEC will examine the results from the 1st phase and evaluate what has been delivered in the specific timeline and how the applicants met the milestones/deliverables. After positive evaluation, the SEC will validate projects for the second phase grant.

The total budget of 1.5 Mio€ funding from the European Commission allows for 4 projects to be funded (375 000 € per project).

The involved industry partners who identified a challenge will join the consortium of applicants once selection is made by the SEC and will co-fund (in cash and in kind) the granted project.

THE NETWORKING EVENT FOR THE RDR CHALLENGES CALL WILL BE HELD ON 3rd MARCH 2020 IN PARIS

For more informations, please click here: http://www.ejprarediseases.org/index.php/funding-schemes/rare-diseases-challenges/

Networking Support Scheme is open

Tuesday, March 3, 2020,

The EJP RD (European Joint Program Rare Diseases) project has opened (on a continuous basis-no deadline) a “call” to provide financial support for organizing workshops to share knowledge on rare diseases.

 Eligible applicants to apply for the NSS are health care professionals, researchers and patient advocacy organizations from the following countries involved in the EJP RD (in alphabetical order): Armenia*, Austria, Belgium, Bulgaria*, Croatia*, Czech Republic*, Denmark, Estonia*, Finland, France, Germany, Georgia*, Greece, Hungary*, Ireland, Israel, Italy, Latvia*, Lithuania*, Luxembourg, Malta*, Norway, Poland*, Portugal, Romania*, Serbia*, Slovakia*, Slovenia*, Spain, Sweden, Switzerland, The Netherlands, Turkey*, United Kingdom.

The application template with the link to the electronic proposal submission system
ProjectNet light can be found at the EJP RD website: http://www.ejprarediseases.org/index.php/networking-support/ 

ANNOUNCEMENT JOINT TRANSNATIONAL CALL 2020

Monday, December 16, 2019,

“Multidisciplinary Research Projects on Personalised Medicine –

Pre-/Clinical research, Big Data and ICT, Implementation and User’s Perspective”


ERA PerMed is an ERA-NET Cofund, supported by 32 partners of 23 countries and cofunded by the European Commission (EC). The funding organisations participating in this call particularly wish to promote innovative interdisciplinary collaboration and to encourage translational research proposals. The available budget for this call is 27 Mio € (approx.).


Opening of online submission tool: 16 December 2019

Submission deadline for pre-proposals: 5 March 2020 (17:00 CET) 

Submission deadline for full-proposals: 15 June 2020 (17:00 CEST)

For more informations, click here: ERA PerMed website 

November 2019 Newsletter is now online!

Friday, November 29, 2019,

ECRIN's newsletter provides relevant updates on ECRIN's work. 

Click here for the new issue: November 2019 

To sign up, please click here.

1